HALOZYME THERAPEUTICS, INC. Available-for-sale Securities, Gross Unrealized Loss
HALOZYME THERAPEUTICS, INC. (HALO) reported Available-for-sale Securities, Gross Unrealized Loss of $57.00 thousand for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2015-03-02
- HALOZYME THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2014-09-30 was $42.00K.
- HALOZYME THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2014-06-30 was -$27.00K.
- HALOZYME THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2014-03-31 was $42.00K.
- HALOZYME THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2013-12-31 was $500.00.
- HALOZYME THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2013 was $3.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month | Available-for-sale Securities, Gross Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2014-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $15.00K derived: sum of 2 quarters · filed 2014-11-10 | $57.00K 10-Q · filed 2014-11-10 | $57.50K derived: sum of 4 quarters · filed 2015-03-02 | |
| 2014-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $15.00K 10-Q · filed 2014-08-11 | $15.50K derived: sum of 3 quarters · filed 2015-03-02 | ||
| 2014-03-31 | $42.00K 10-Q · filed 2014-05-12 | $42.50K derived: sum of 2 quarters · filed 2015-03-02 | |||
| 2013-12-31 | $500.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $3.00K 10-K · filed 2015-03-02 | $3.13K 10-K · filed 2014-02-28 | ||
| 2013-09-30 | $2.50K 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |